المؤلفون: Shumitskaya, Anastasia A., Kozlov, Vadim O., Selivanov, Nikita. I., Stoumpos, Constantinos C., Zapasskii, Valery S., Kapitonov, Yury V., Ryzhov, Ivan I.

مصطلحات موضوعية: Condensed Matter - Materials Science, Condensed Matter - Other Condensed Matter

الوصف: The spin degree of freedom of charge carriers in halide-perovskite semiconductors can be highly useful for information photonics applications. The Faraday effect is known to be the best indicator of paramagnetism of the material and of the spin-light interaction. In this work, the Faraday effect is demonstrated, for the first time, in a hybrid organic-inorganic halide perovskite MAPbI3 (MA+=CH3NH+3). The Faraday rotation and birefringence were measured across the tetragonal-cubic phase transition at 327 K. The Faraday rotation is strongly suppressed below the phase transition temperature due to anisotropy (linear birefringence) of the tetragonal crystal phase. The situation changes drastically above the phase transition temperature, when the crystal becomes optically isotropic. The emerging Faraday rotation obeys the Curie law, demonstrating its population-related paramagnetic nature. This observation opens new prospects for application of these systems and for their investigations using methods of the polarization noise spectroscopy applicable to optically anisotropic materials.
Comment: 12 pages, 5 figures

الوصول الحر: http://arxiv.org/abs/2309.03125Test

المؤلفون: Motzer, Robert J., Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Alekseev, Boris, Rha, Sun Young, Merchan, Jaime, Goh, Jeffrey C., Lalani, Aly Khan A., De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung Hoo, Gurney, Howard, Mendez Vidal, Maria Jose, Kopyltsov, Evgeny, Tjulandin, Sergei, Gordoa, Teresa Alonso, Kozlov, Vadim, Alyasova, Anna, Winquist, Eric, Maroto, Pablo, Kim, Miso, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Rodriguez-Lopez, Karla, Burgents, Joseph, He, Cixin, Okpara, Chinyere E., McKenzie, Jodi, Choueiri, Toni

المصدر: Motzer , R J , Porta , C , Eto , M , Powles , T , Grünwald , V , Hutson , T E , Alekseev , B , Rha , S Y , Merchan , J , Goh , J C , Lalani , A K A , De Giorgi , U , Melichar , B , Hong , S H , Gurney , H , Mendez Vidal , M J , Kopyltsov , E , Tjulandin , S , Gordoa , T A , Kozlov , V , Alyasova , A , Winquist , E , ....

الوصف: Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up of 23 months from the primary analysis, we report results from the lenvatinib plus pembrolizumab versus sunitinib comparison of CLEAR. Treatment-naïve patients with aRCC were randomly assigned to receive lenvatinib (20 mg orally once daily in 21-day cycles) plus pembrolizumab (200 mg intravenously once every 3 weeks) or sunitinib (50 mg orally once daily [4 weeks on/2 weeks off]). At this data cutoff date (July 31, 2022), the OS hazard ratio (HR) was 0.79 (95% CI, 0.63 to 0.99). The median OS (95% CI) was 53.7 months (95% CI, 48.7 to not estimable [NE]) with lenvatinib plus pembrolizumab versus 54.3 months (95% CI, 40.9 to NE) with sunitinib; 36-month OS rates (95% CI) were 66.4% (95% CI, 61.1 to 71.2) and 60.2% (95% CI, 54.6 to 65.2), respectively. The median progression-free survival (95% CI) was 23.9 months (95% CI, 20.8 to 27.7) with lenvatinib plus pembrolizumab and 9.2 months (95% CI, 6.0 to 11.0) with sunitinib (HR, 0.47 [95% CI, 0.38 to 0.57]). Objective response rate also favored the combination over sunitinib (71.3% v 36.7%; relative risk 1.94 [95% CI, 1.67 to 2.26]). Treatment-emergent adverse events occurred in >90% of patients who received either treatment. In conclusion, lenvatinib plus pembrolizumab achieved consistent, durable benefit with a manageable safety profile in treatment-naïve patients with aRCC.

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1200/JCO.23.01569Test
https://researchers.mq.edu.au/en/publications/fa0904f7-1e52-4edd-abcc-7067409e1516Test
https://research-management.mq.edu.au/ws/files/340649651/Publisher_version_open_access_.pdfTest
http://www.scopus.com/inward/record.url?scp=85189700658&partnerID=8YFLogxKTest

المؤلفون: Motzer, Robert J, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Alekseev, Boris, Rha, Sun Young, Merchan, Jaime, Goh, Jeffrey C, Lalani, Aly-Khan A, De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Méndez-Vidal, María José, Kopyltsov, Evgeny, Tjulandin, Sergei, Gordoa, Teresa Alonso, Kozlov, Vadim, Alyasova, Anna, Winquist, Eric, Maroto, Pablo, Kim, Miso, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Rodriguez-Lopez, Karla, Burgents, Joseph, He, Cixin, Okpara, Chinyere E, McKenzie, Jodi, Choueiri, Toni K, CLEAR Trial Investigators

المساهمون: Gennigens, Christine

المصدر: Journal of Clinical Oncology, JCO2301569 (2024-01-16)

مصطلحات موضوعية: Cancer Research, Oncology, Human health sciences, Sciences de la santé humaine, Oncologie

الوصف: Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up of 23 months from the primary analysis, we report results from the lenvatinib plus pembrolizumab versus sunitinib comparison of CLEAR. Treatment-naïve patients with aRCC were randomly assigned to receive lenvatinib (20 mg orally once daily in 21-day cycles) plus pembrolizumab (200 mg intravenously once every 3 weeks) or sunitinib (50 mg orally once daily [4 weeks on/2 weeks off]). At this data cutoff date (July 31, 2022), the OS hazard ratio (HR) was 0.79 (95% CI, 0.63 to 0.99). The median OS (95% CI) was 53.7 months (95% CI, 48.7 to not estimable [NE]) with lenvatinib plus pembrolizumab versus 54.3 months (95% CI, 40.9 to NE) with sunitinib; 36-month OS rates (95% CI) were 66.4% (95% CI, 61.1 to 71.2) and 60.2% (95% CI, 54.6 to 65.2), respectively. The median progression-free survival (95% CI) was 23.9 months (95% CI, 20.8 to 27.7) with lenvatinib plus pembrolizumab and 9.2 months (95% CI, 6.0 to 11.0) with sunitinib (HR, 0.47 [95% CI, 0.38 to 0.57]). Objective response rate also favored the combination over sunitinib (71.3% v 36.7%; relative risk 1.94 [95% CI, 1.67 to 2.26]). Treatment-emergent adverse events occurred in >90% of patients who received either treatment. In conclusion, lenvatinib plus pembrolizumab achieved consistent, durable benefit with a manageable safety profile in treatment-naïve patients with aRCC.

العلاقة: https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.01569Test; urn:issn:0732-183X; urn:issn:1527-7755

الوصول الحر: https://orbi.uliege.be/handle/2268/315809Test

المؤلفون: Lopes, Renato D, Higano, Celestia S, Slovin, Susan F, Nelson, Adam J, Bigelow, Robert, Sørensen, Per S, Melloni, Chiara, Goodman, Shaun G, Evans, Christopher P, Nilsson, Jan, Bhatt, Deepak L, Clarke, Noel W, Olesen, Tine K, Doyle-Olsen, Belinda T, Kristensen, Henriette, Arney, Lauren, Roe, Matthew T, Alexander, John H, Mol-Arts, Mirjam, Mansor-Lefebvre, Samreen, Zubovskiy, Konstantin, Blemings, Allan, Dugi, Klaus, Bloomfield, Gerald, Kontos, Chris, DeVore, Adam, Jordan, Dedrick, Kolls, Bradley, Matthews, Robin, Mehta, Rajendra, Povsic, Thomas J, Morse, Michael, Mahaffey, Kenneth W, Halabi, Susan, Leong, Darryl, Klotz, Laurence, Fleshner, Neil, Jansz, Godfrey, Giddens, Jonathan, Egerdie, Russell, Chin, Joseph, Zadra, Joseph, Casey, Richard, Simard, Jean, Niazi, Tamim, Martin, André-Guy, Babjuk, Marek, Hajek, Jaroslav, Klecka, Jiri, Kubes, Jiri, Schraml, Jan, Jakesova, Jitka, Vanasek, Jaroslav, Melichar, Bohuslav, Seikkula, Heikki, Abdiche, Manouar Samir, Colombel, Marc, Debourdeau, Philippe, Robert, Gregoire, Villers, Arnauld, Ploussard, Guillaume, Pradere, Benjamin, Bruyere, Franck, Descotes, Jean-Luc, Ouzaid, Idir, Winter, Alexander, Hanitzsch, Herbert, Sperling, Herbert, Eckert, Ralf, Hammerer, Peter, Stagge, Elke, Seseke, Florian, Szymula, Silvio, Bamias, Aristotelis, Thanos, Anastasios, Hatzimouratidis, Konstantinos, Mamoulakis, Charalambos, Kalofonos, Haralabos, Oszukowska, Elzbieta, Madziarska, Katarzyna, Fijuth, Jacek, Obarzanowski, Mateusz, Alekseev, Boris, Atduev, Vagif, Pushkar, Dmitri, Veliev, Evgeniy, Zyryanov, Alexander, Petrov, Sergey, Kopyltsov, Evgeny, Kozlov, Vadim, Macko, Ladislav, Dubravicky, Jozef, Polak, Richard, Mir, Obaidullah, Vargovcak, Marek, Mincik, Ivan, Kliment, Jan, Goncalves, Frederico, Mikulas, Juraj, Sokol, Roman

المصدر: Circulation. 144(16)

مصطلحات موضوعية: Cancer, Clinical Trials and Supportive Activities, Patient Safety, Aging, Prostate Cancer, Urologic Diseases, Cardiovascular, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Aged, Humans, Leuprolide, Male, Oligopeptides, Prospective Studies, Prostatic Neoplasms, agonists, atherosclerosis, cardiotoxicity, drug therapy, gonadotropin-releasing hormone, prostatic neoplasms, PRONOUNCE Study Investigators, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Public Health and Health Services, Cardiovascular System & Hematology

الوصف: BackgroundThe relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial.MethodsIn this international, multicenter, prospective, randomized, open-label trial, men with prostate cancer and concomitant atherosclerotic cardiovascular disease were randomly assigned 1:1 to receive the GnRH antagonist degarelix or the GnRH agonist leuprolide for 12 months. The primary outcome was the time to first adjudicated major adverse cardiovascular event (composite of death, myocardial infarction, or stroke) through 12 months.ResultsBecause of slower-than-projected enrollment and fewer-than-projected primary outcome events, enrollment was stopped before the 900 planned participants were accrued. From May 3, 2016, to April 16, 2020, a total of 545 patients from 113 sites across 12 countries were randomly selected. Baseline characteristics were balanced between study groups. The median age was 73 years, 49.8% had localized prostate cancer; 26.3% had locally advanced disease, and 20.4% had metastatic disease. A major adverse cardiovascular event occurred in 15 (5.5%) patients assigned to degarelix and 11 (4.1%) patients assigned to leuprolide (hazard ratio, 1.28 [95% CI, 0.59-2.79]; P=0.53).ConclusionsPRONOUNCE (A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease) is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in patients with prostate cancer. The study was terminated prematurely because of the smaller than planned number of participants and events, and no difference in major adverse cardiovascular events at 1 year between patients assigned to degarelix or leuprolide was observed. The relative cardiovascular safety of GnRH antagonists and agonists remains unresolved. Registration: URL: https://www.clinicaltrials.govTest; Unique identifier: NCT02663908.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/8811h1xdTest

المؤلفون: Grünwald, Viktor, Powles, Thomas, Kopyltsov, Evgeny, Kozlov, Vadim, Alonso-Gordoa, Teresa, Eto, Masatoshi, Hutson, Thomas, Motzer, Robert, Winquist, Eric, Maroto, Pablo, Keam, Bhumsuk, Procopio, Giuseppe, Wong, Shirley, Melichar, Bohuslav, Rolland, Frederic, Oya, Mototsugu, Rodriguez-Lopez, Karla, Saito, Kenichi, McKenzie, Jodi, Porta, Camillo

المصدر: European Urology Oncology ; volume 6, issue 4, page 437-446 ; ISSN 2588-9311

مصطلحات موضوعية: Urology, Radiology, Nuclear Medicine and imaging, Oncology, Surgery

الإتاحة: https://doi.org/10.1016/j.euo.2023.01.010Test
https://api.elsevier.com/content/article/PII:S2588931123000287?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2588931123000287?httpAccept=text/plainTest

المؤلفون: Pustylnyak, Vladimir O., Alekseenok, Efim Y., Perevalova, Alina M., Kozlov, Vadim V., Gulyaeva, Lyudmila F.

المساهمون: Ministry of Education and Science of the Russian Federation, Russian Science Foundation

المصدر: Heliyon ; volume 9, issue 8, page e19044 ; ISSN 2405-8440

الإتاحة: https://doi.org/10.1016/j.heliyon.2023.e19044Test
https://api.elsevier.com/content/article/PII:S2405844023062527?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2405844023062527?httpAccept=text/plainTest

المؤلفون: Minatta, Jose, Samol, Jens, Moiseenko, Fedor, Demedts, Ingel, Kozlov, Vadim, Mark, Michael, Rajappa, Senthil, Kahangire, Doreen A., Madondo, Mutsa, Bailey, Tom, Wallis, Hannah, Erman, Mustafa, Zukin, Mauro

المصدر: Journal of Thoracic Oncology ; volume 18, issue 3, page S9 ; ISSN 1556-0864

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology

الإتاحة: https://doi.org/10.1016/j.jtho.2023.01.030Test
https://api.elsevier.com/content/article/PII:S1556086423000394?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1556086423000394?httpAccept=text/plainTest

المؤلفون: Perevalova, Alina M., Kononchuk, Vladislav V., Kalinina, Tatiana S., Kozlov, Vadim V., Gulyaeva, Lyudmila F., Pustylnyak, Vladimir O.

المصدر: Cancers; Jun2024, Vol. 16 Issue 12, p2208, 15p

مصطلحات موضوعية: SQUAMOUS cell carcinoma, DATA analysis, RESEARCH funding, IMMUNOTHERAPY, SMOKING, MICRORNA, TUMOR markers, CANCER patients, REVERSE transcriptase polymerase chain reaction, MANN Whitney U Test, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, BIOINFORMATICS, MESSENGER RNA, GENE expression, LUNG tumors, DRUG efficacy, STATISTICS, COLLECTION & preservation of biological specimens, DATA analysis software, IMMUNITY

مستخلص: Simple Summary: The impact of smoking on the development of lung cancer is widely acknowledged; however, all of the molecular processes behind this effect, as well as their possible clinical applications, are still unclear. The current study aimed to identify and describe a potential smoking-related molecular mechanism in squamous cell lung cancer, with its possible connection to the immunotherapy response. By analyzing bioinformatic data from different databases and conducting experiments on clinical tumor samples, we demonstrated the connection between the microRNA mir-301a and the transcription factor IRF1, which demonstrated the capacity to affect many immune pathways in lung cancer and the efficacy of treatment with immune checkpoint inhibitors. These findings not only clarify certain molecular characteristics of squamous cell lung cancer but also open up new avenues for future immunotherapy research. Smoking is an established risk factor for a variety of malignant tumors, the most well-known of which is lung cancer. Various molecular interactions are known to link tobacco smoke exposure to lung cancer, but new data are still emerging on the effects of smoking on lung cancer development, progression, and tumor response to therapy. In this study, we reveal in further detail the previously established association between smoking and hsa-mir-301a activity in lung squamous cell carcinoma, LUSC. Using different bioinformatic tools, we identified IRF1 as a key smoking-regulated target of hsa-mir-301a in LUSC. We further confirmed this relationship experimentally using clinical LUSC tissue samples and intact lung tissue samples. Thus, increased hsa-mir-301a levels, decreased IRF1 mRNA levels, and their negative correlation were shown in LUSC tumor samples. Additional bioinformatic investigation for potential pathways impacted by such a mechanism demonstrated IRF1's multifaceted role in controlling the antitumor immune response in LUSC. IRF1 was then shown to affect tumor immune infiltration, the expression of immune checkpoint molecules, and the efficacy of immune checkpoint blockade therapy. As a result, here we suggest a smoking-regulated mir301a/IRF1 molecular axis that could modulate the antitumor immune response and immunotherapy efficacy in LUSC, opening up novel opportunities for future research. [ABSTRACT FROM AUTHOR]

: Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Motzer, Robert J., Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Alekseev, Boris, Rha, Sun Young, Merchan, Jaime, Goh, Jeffrey C., Lalani, Aly-Khan A., De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Méndez-Vidal, María José, Kopyltsov, Evgeny, Tjulandin, Sergei, Gordoa, Teresa Alonso, Kozlov, Vadim

المصدر: Journal of Clinical Oncology; 4/10/2024, Vol. 42 Issue 11, p1222-1228, 13p

المؤلفون: Shumitskaya, Anastasia A.¹ (AUTHOR), Kozlov, Vadim O.¹ (AUTHOR) v.o.kozlov@spbu.ru, Selivanov, Nikita. I.¹ (AUTHOR), Stoumpos, Constantinos C.^1,2 (AUTHOR), Zapasskii, Valerii S.¹ (AUTHOR), Kapitonov, Yury V.¹ (AUTHOR), Ryzhov, Ivan I.¹ (AUTHOR)

المصدر: Advanced Optical Materials. 4/4/2024, Vol. 12 Issue 10, p1-5. 5p.

مصطلحات موضوعية: *PHASE transitions, *SINGLE crystals, *TRANSITION temperature, *POLARIZATION spectroscopy, *PEROVSKITE, *FARADAY effect

مستخلص: The spin degree of freedom of charge carriers in halide‐perovskite semiconductors can be highly useful for information photonics applications. The Faraday effect is known to be the best indicator of paramagnetism of the material and of the spin‐light interaction. In this work, the Faraday effect is demonstrated, for the first time, in a hybrid organic–inorganic halide perovskite MAPbI3 (MA+ = CH3NH3+$_3^+$). The Faraday rotation and birefringence are measured across the tetragonal‐cubic phase transition at 327 K. The Faraday rotation is strongly suppressed below the phase transition temperature due to anisotropy (linear birefringence) of the tetragonal crystal phase. The situation changes drastically above the phase transition temperature, when the crystal becomes optically isotropic. The emerging Faraday rotation obeys the Curie law, demonstrating its population‐related paramagnetic nature. This observation opens new prospects for application of these systems and for their investigations using methods of the polarization noise spectroscopy applicable to optically anisotropic materials. [ABSTRACT FROM AUTHOR]